Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium Bromide on Exercise Endurance in COPD
NCT00500318Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Aclidinium Bromide with Placebo (2 arms). Primary endpoint: Change From Baseline in Exercise Endurance Time (ET) at 6 weeks. Started Jul 2007; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00500318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500318.